TD Cowen made an adjustment to Danaher Corporation's (NYSE:DHR) financial outlook by reducing the price target from $315.00 to $260.00. Despite this change, the firm has maintained a Buy rating on the company's shares.

Stifel analysts reduced the price target for Danaher Corporation shares (NYSE:DHR) to $260 from the previous target of $265, while maintaining a Hold rating on the stock. The new target sits within the broader analyst range of $240-$310 for the $165 billion life sciences company.

Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in biotechnology and life sciences.

Danaher (DHR) stock trades ~5% lower as the company, with its Q4 2024 results, projects a sales contraction in the current quarter. Read more here.

TD Cowen analyst Dan Brennan lowered the firm’s price target on Danaher (DHR) to $260 from $315 and keeps a Buy rating on the shares. The firm

RBC Capital analyst Conor McNamara lowered the firm’s price target on Danaher (DHR) to $277 from $299 but keeps an Outperform rating on the

Danaher Corporation DHR reported weaker-than-expected fourth-quarter earnings on Wednesday. The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

U.S. stocks slipped after the Federal Reserve held its main interest rate steady and broke a run of cuts that began in September

This positive outcome has rippled through the industry, with Danaher and Thermo Fisher anticipating their own earnings reports later this week. Analysts have weighed in on Sartorius's results, attributing the impressive fourth quarter to high demand for consumables,

Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced ...

Danaher Corporation (NYSE:DHR) stock has experienced a notable downturn, reaching a 52-week low of $225.36. With a market capitalization of $163 billion, InvestingPro analysis indicates the stock is currently trading above its Fair Value.

Barclays lowered the firm’s price target on Danaher (DHR) to $240 from $275 and keeps an Equal Weight rating on the shares. The company